EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling

Panagiota Tsiri iD, Bruno Crestani, Arnaud Mailleux, Argyrios Tzouvelekis

Diagnostics · 14.05.2026 · 16 (10) · 1493

DOI: 10.3390/diagnostics16101493 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 14.05.2026. Verfasst von Panagiota Tsiri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis is increasingly viewed as a lung-centered disease influenced by systemic metabolic and inflammatory context. Adipose tissue, through its endocrine, paracrine, and immunometabolic functions, may act as a systemic modifier rather than a primary initiator of fibrotic remodeling. Epidemiologic and imaging studies link visceral adiposity, body composition, and adipose-related mediators such as leptin and IL-6 with subclinical interstitial abnormalities and outcomes in fibrotic ILD, while genetic and clinical data support a context-dependent protective role for adiponectin signaling. Mechanistic evidence suggests that adipose dysfunction may influence fibrotic remodeling through adipokine imbalance, inflammasome activation, perivascular inflammation, profibrotic macrophage polarization, epithelial maladaptation, cellular senescence, and fibroblast metabolic reprogramming. These pathways may converge to sustain myofibroblast activation and extracellular matrix deposition. Clinically, adipose dysfunction overlaps with common ILD comorbidities and may inform metabolic phenotyping, biomarker development, and patient stratification. Therapeutic implications remain investigational, with the strongest rationale supporting metabolic reprogramming strategies and biomarker-enriched studies rather than routine adipose-targeted therapy. Overall, the adipose–lung axis provides a framework for integrating systemic metabolic biology into the pathogenesis and clinical management of fibrotic ILD.

Schlagwörter

Stichwörter der Autor:innen

adipokinesadipose tissuebiomarkersfibrotic ILDmetabolic reprogrammingpulmonary fibrosis

Autor:innen und Institutionen

  • Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece.
  • Centre de Recherche sur l'Inflammation, Université Paris Cité, Inserm, 75018 Paris, France.
  • Service de Pneumologie et Transplantation, Centre de Référence Constitutif des Maladies Pulmonaires Rares, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 75018 Paris, France.
  • Department of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT 06511, USA.

ORCID-Profile: Panagiota Tsiri

Zitieren

APA

Tsiri, P., Crestani, B., Mailleux, A., & Tzouvelekis, A. (2026). Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling. Diagnostics, 16(10), 1493. https://doi.org/10.3390/diagnostics16101493

Vancouver

Tsiri P, Crestani B, Mailleux A, Tzouvelekis A. Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling. Diagnostics. 2026;16(10):1493. doi:10.3390/diagnostics16101493

BibTeX
@article{Tsiri2026,
  author = {Tsiri, Panagiota and Crestani, Bruno and Mailleux, Arnaud and Tzouvelekis, Argyrios},
  title = {Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {10},
  pages = {1493},
  doi = {10.3390/diagnostics16101493}
}
Kostenlos starten →